Cargando…

Complete and durable response to crizotinib in a patient with malignant pleural mesothelioma harboring CD74-ROS1 fusion

Malignant pleural mesothelioma (MPM) is a rare and deadly malignancy with an extremely poor prognosis. The median overall survival (OS) of this disease is 12–18 months. However, the oncogenic driver mutations of MPM are rarely understood, and the targeted therapy for it is still under investigation....

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Xuehua, You, Mengxing, Meng, Erhong, Wang, Shunyou, Niu, Beifang, Huang, Weiming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Letter to the Editors
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349100/ https://www.ncbi.nlm.nih.gov/pubmed/35648195 http://dx.doi.org/10.1007/s00432-022-04076-0

Ejemplares similares

A patient with classic biphasic pulmonary blastoma harboring CD74–ROS1 fusion responds to crizotinib
por: Meng, Zhaoting, et al.
Publicado: (2017)

Refractory and metastatic infantile fibrosarcoma harboring LMNA–NTRK1 fusion shows complete and durable response to crizotinib
por: Bender, Jonathan, et al.
Publicado: (2019)

Combined effect of cabozantinib and gefitinib in crizotinib‐resistant lung tumors harboring ROS1 fusions
por: Kato, Yuka, et al.
Publicado: (2018)

Durable response to crizotinib in an advanced lung adenocarcinoma patient harboring rare CD47-MET fusion: a case report
por: Liu, Junfang, et al.
Publicado: (2022)

Response to crizotinib in a patient with metastatic lung spindle cell carcinoma harboring TPM3-ROS1 fusion
por: Cai, Cun-Liang, et al.
Publicado: (2019)

Role of MIF/CD74 signaling pathway in the development of pleural mesothelioma
por: D'Amato-Brito, Cintia, et al.
Publicado: (2016)

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
por: Mansfield, A. S., et al.
Publicado: (2022)

Case report: complete remission with crizotinib in ROS1 fusion-positive sinonasal mucosal melanoma
por: Cao, Jun, et al.
Publicado: (2022)

CD74: a new prognostic factor for patients with malignant pleural mesothelioma
por: Otterstrom, C, et al.
Publicado: (2014)

A Novel ROS1-FBXL17 Fusion Co-Existing with CD74-ROS1 Fusion May Improve Sensitivity to Crizotinib and Prolong Progression-Free Survival of Patients with Lung Adenocarcinoma
por: Lan, Shaowei, et al.
Publicado: (2020)

Response to crizotinib in a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant
por: Zhao, Zheng, et al.
Publicado: (2017)

A case of lung adenocarcinoma with a novel CD74‐ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib
por: Hashiguchi, Mizuha Haraguchi, et al.
Publicado: (2021)

A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy
por: Mönch, Dina, et al.
Publicado: (2018)

Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements
por: Zhang, Yongchang, et al.
Publicado: (2022)

A case of ROS1‐rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib
por: Tachi, Hiroaki, et al.
Publicado: (2020)

Crizotinib in Sarcomatous Malignancies Harboring ALK Fusion With a Definitive Partner(s): Response and Efficacy
por: Wu, Jinchun, et al.
Publicado: (2021)

Durable Response to Crizotinib in a Patient with Pulmonary Adenocarcinoma Harboring MET Intron 14 Mutation: A Case Report
por: Leyrat, Brice, et al.
Publicado: (2021)

Different Types of ROS1 Fusion Partners Yield Comparable Efficacy to Crizotinib
por: He, Yueming, et al.
Publicado: (2019)

A primary undifferentiated pleomorphic sarcoma of the lumbosacral region harboring a LMNA-NTRK1 gene fusion with durable clinical response to crizotinib: a case report
por: Zhou, Ning, et al.
Publicado: (2018)

Synergistic Effects of Crizotinib and Temozolomide in Experimental FIG-ROS1 Fusion-Positive Glioblastoma
por: Das, Arabinda, et al.
Publicado: (2015)

Case Report: Short-Term Response to First-Line Crizotinib Monotherapy in a Metastatic Lung Adenocarcinoma Patient Harboring a Novel TPR-ROS1 Fusion
por: Wei, Shuli, et al.
Publicado: (2022)

Effective Treatment with Cabozantinib in an Advanced Non-Small-Cell Lung Cancer Patient Harboring a CD74-ROS1 Fusion: A Case Report
por: Wang, Gang, et al.
Publicado: (2020)

Survival Effect of Complete Multimodal Therapy in Malignant Pleural Mesothelioma
por: Sayan, Muhammet, et al.
Publicado: (2022)

Dramatic response to local radiotherapy in a refractory metastatic mediastinal yolk sac tumor patient harboring a germline BRCA2 frameshift mutation: a case report
por: Cheng, Xi, et al.
Publicado: (2022)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma
por: Ota, Takayo, et al.
Publicado: (2019)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers
por: Sorino, Claudio, et al.
Publicado: (2023)

ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib
por: Xu, Shuguang, et al.
Publicado: (2019)

Elevation of tumor mutation burden in ROS1-fusion lung adenocarcinoma resistant to crizotinib: A case report
por: Yang, Tao, et al.
Publicado: (2018)

Unique SLC12A2-ROS1 fusion is associated with marked response to crizotinib in lung adenocarcinoma
por: Ribeiro, Maurício Fernando Silva Almeida, et al.
Publicado: (2022)

STRN-ALK Fusion in a Case of Malignant Peritoneal Mesothelioma: Mixed Response to Crizotinib, Mode of Resistance, and Brigatinib Sequential Therapy
por: Gerthofer, Valeria, et al.
Publicado: (2021)

Malignant pleural mesothelioma in Italy
por: Bianchi, Claudio, et al.
Publicado: (2009)

Pleural mesothelioma – case report
por: Klawiter, Anna, et al.
Publicado: (2010)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Malignant pleural mesothelioma: an update
por: Hajj, Glaucia N. M., et al.
Publicado: (2021)

Malignant pleural mesothelioma in situ
por: Ando, Kohei, et al.
Publicado: (2022)

Extrathoracic Metastases in Pleural Mesothelioma
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2023)

Pleural Mesothelioma in the Era of Immunotherapy
por: Chevallier, Mathieu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lr14g552sejsn6u5pg47319qr4